Browse ICAM1

Summary
SymbolICAM1
Nameintercellular adhesion molecule 1
Aliases CD54; human rhinovirus receptor; P3.58; ICAM-1; cell surface glycoprotein P3.58; intercellular adhesion mole ......
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type I membrane protein.
Domain PF03921 Intercellular adhesion molecule (ICAM)
Function

ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2). During leukocyte trans-endothelial migration, ICAM1 engagement promotes the assembly of endothelial apical cups through ARHGEF26/SGEF and RHOG activation. ; FUNCTION: (Microbial infection) Acts as a receptor for major receptor group rhinovirus A-B capsid proteins. ; FUNCTION: (Microbial infection) Acts as a receptor for Coxsackievirus A21 capsid proteins. ; FUNCTION: (Microbial infection) Upon Kaposi's sarcoma-associated herpesvirus/HHV-8 infection, is degraded by viral E3 ubiquitin ligase MIR2, presumably to prevent lysis of infected cells by cytotoxic T-lymphocytes and NK cell.

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0001541 ovarian follicle development
GO:0001666 response to hypoxia
GO:0001678 cellular glucose homeostasis
GO:0001885 endothelial cell development
GO:0001906 cell killing
GO:0001909 leukocyte mediated cytotoxicity
GO:0001910 regulation of leukocyte mediated cytotoxicity
GO:0001975 response to amphetamine
GO:0002064 epithelial cell development
GO:0002237 response to molecule of bacterial origin
GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002286 T cell activation involved in immune response
GO:0002291 T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell
GO:0002366 leukocyte activation involved in immune response
GO:0002437 inflammatory response to antigenic stimulus
GO:0002438 acute inflammatory response to antigenic stimulus
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002456 T cell mediated immunity
GO:0002457 T cell antigen processing and presentation
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002526 acute inflammatory response
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002691 regulation of cellular extravasation
GO:0002693 positive regulation of cellular extravasation
GO:0003013 circulatory system process
GO:0003018 vascular process in circulatory system
GO:0003158 endothelium development
GO:0006809 nitric oxide biosynthetic process
GO:0006816 calcium ion transport
GO:0007015 actin filament organization
GO:0007157 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules
GO:0007159 leukocyte cell-cell adhesion
GO:0007548 sex differentiation
GO:0007568 aging
GO:0007569 cell aging
GO:0007605 sensory perception of sound
GO:0008015 blood circulation
GO:0008064 regulation of actin polymerization or depolymerization
GO:0008154 actin polymerization or depolymerization
GO:0008360 regulation of cell shape
GO:0008406 gonad development
GO:0008584 male gonad development
GO:0008585 female gonad development
GO:0008625 extrinsic apoptotic signaling pathway via death domain receptors
GO:0009314 response to radiation
GO:0009743 response to carbohydrate
GO:0009746 response to hexose
GO:0009749 response to glucose
GO:0009991 response to extracellular stimulus
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0010212 response to ionizing radiation
GO:0010477 response to sulfur dioxide
GO:0010959 regulation of metal ion transport
GO:0014075 response to amine
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0019058 viral life cycle
GO:0019062 virion attachment to host cell
GO:0019229 regulation of vasoconstriction
GO:0019882 antigen processing and presentation
GO:0022406 membrane docking
GO:0022602 ovulation cycle process
GO:0022604 regulation of cell morphogenesis
GO:0022614 membrane to membrane docking
GO:0030031 cell projection assembly
GO:0030041 actin filament polymerization
GO:0030198 extracellular matrix organization
GO:0030260 entry into host cell
GO:0030335 positive regulation of cell migration
GO:0030832 regulation of actin filament length
GO:0030833 regulation of actin filament polymerization
GO:0030838 positive regulation of actin filament polymerization
GO:0031334 positive regulation of protein complex assembly
GO:0031341 regulation of cell killing
GO:0031529 ruffle organization
GO:0031667 response to nutrient levels
GO:0031668 cellular response to extracellular stimulus
GO:0031669 cellular response to nutrient levels
GO:0032271 regulation of protein polymerization
GO:0032273 positive regulation of protein polymerization
GO:0032496 response to lipopolysaccharide
GO:0032535 regulation of cellular component size
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0033500 carbohydrate homeostasis
GO:0033627 cell adhesion mediated by integrin
GO:0034284 response to monosaccharide
GO:0034341 response to interferon-gamma
GO:0034612 response to tumor necrosis factor
GO:0034698 response to gonadotropin
GO:0035150 regulation of tube size
GO:0036293 response to decreased oxygen levels
GO:0036294 cellular response to decreased oxygen levels
GO:0040017 positive regulation of locomotion
GO:0042110 T cell activation
GO:0042310 vasoconstriction
GO:0042493 response to drug
GO:0042593 glucose homeostasis
GO:0042698 ovulation cycle
GO:0043062 extracellular structure organization
GO:0043200 response to amino acid
GO:0043254 regulation of protein complex assembly
GO:0043271 negative regulation of ion transport
GO:0043279 response to alkaloid
GO:0043410 positive regulation of MAPK cascade
GO:0044057 regulation of system process
GO:0044089 positive regulation of cellular component biogenesis
GO:0044406 adhesion of symbiont to host
GO:0044409 entry into host
GO:0044650 adhesion of symbiont to host cell
GO:0045123 cellular extravasation
GO:0045137 development of primary sexual characteristics
GO:0045428 regulation of nitric oxide biosynthetic process
GO:0045429 positive regulation of nitric oxide biosynthetic process
GO:0045446 endothelial cell differentiation
GO:0045471 response to ethanol
GO:0045907 positive regulation of vasoconstriction
GO:0046209 nitric oxide metabolic process
GO:0046545 development of primary female sexual characteristics
GO:0046546 development of primary male sexual characteristics
GO:0046660 female sex differentiation
GO:0046661 male sex differentiation
GO:0046688 response to copper ion
GO:0046718 viral entry into host cell
GO:0046813 receptor-mediated virion attachment to host cell
GO:0048511 rhythmic process
GO:0048608 reproductive structure development
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0050880 regulation of blood vessel size
GO:0050900 leukocyte migration
GO:0050954 sensory perception of mechanical stimulus
GO:0051051 negative regulation of transport
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051092 positive regulation of NF-kappaB transcription factor activity
GO:0051258 protein polymerization
GO:0051272 positive regulation of cellular component movement
GO:0051493 regulation of cytoskeleton organization
GO:0051495 positive regulation of cytoskeleton organization
GO:0051701 interaction with host
GO:0051806 entry into cell of other organism involved in symbiotic interaction
GO:0051828 entry into other organism involved in symbiotic interaction
GO:0051924 regulation of calcium ion transport
GO:0051926 negative regulation of calcium ion transport
GO:0060008 Sertoli cell differentiation
GO:0060009 Sertoli cell development
GO:0060333 interferon-gamma-mediated signaling pathway
GO:0060491 regulation of cell projection assembly
GO:0061028 establishment of endothelial barrier
GO:0061458 reproductive system development
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070482 response to oxygen levels
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070555 response to interleukin-1
GO:0070838 divalent metal ion transport
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071312 cellular response to alkaloid
GO:0071322 cellular response to carbohydrate stimulus
GO:0071326 cellular response to monosaccharide stimulus
GO:0071331 cellular response to hexose stimulus
GO:0071333 cellular response to glucose stimulus
GO:0071346 cellular response to interferon-gamma
GO:0071347 cellular response to interleukin-1
GO:0071356 cellular response to tumor necrosis factor
GO:0071396 cellular response to lipid
GO:0071417 cellular response to organonitrogen compound
GO:0071453 cellular response to oxygen levels
GO:0071456 cellular response to hypoxia
GO:0071496 cellular response to external stimulus
GO:0071593 lymphocyte aggregation
GO:0072511 divalent inorganic cation transport
GO:0072577 endothelial cell apoptotic process
GO:0072593 reactive oxygen species metabolic process
GO:0090066 regulation of anatomical structure size
GO:0097178 ruffle assembly
GO:0097191 extrinsic apoptotic signaling pathway
GO:0097305 response to alcohol
GO:0097368 establishment of Sertoli cell barrier
GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules
GO:1900027 regulation of ruffle assembly
GO:1902041 regulation of extrinsic apoptotic signaling pathway via death domain receptors
GO:1902042 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors
GO:1903409 reactive oxygen species biosynthetic process
GO:1903426 regulation of reactive oxygen species biosynthetic process
GO:1903428 positive regulation of reactive oxygen species biosynthetic process
GO:1903522 regulation of blood circulation
GO:1903524 positive regulation of blood circulation
GO:1904019 epithelial cell apoptotic process
GO:1904035 regulation of epithelial cell apoptotic process
GO:1904036 negative regulation of epithelial cell apoptotic process
GO:1904407 positive regulation of nitric oxide metabolic process
GO:1990267 response to transition metal nanoparticle
GO:2000147 positive regulation of cell motility
GO:2000351 regulation of endothelial cell apoptotic process
GO:2000352 negative regulation of endothelial cell apoptotic process
GO:2000377 regulation of reactive oxygen species metabolic process
GO:2000379 positive regulation of reactive oxygen species metabolic process
GO:2001057 reactive nitrogen species metabolic process
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001236 regulation of extrinsic apoptotic signaling pathway
GO:2001237 negative regulation of extrinsic apoptotic signaling pathway
Molecular Function GO:0001618 virus receptor activity
GO:0005178 integrin binding
GO:0050839 cell adhesion molecule binding
Cellular Component GO:0001772 immunological synapse
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0009897 external side of plasma membrane
GO:0030055 cell-substrate junction
GO:0045121 membrane raft
GO:0098552 side of membrane
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04064 NF-kappa B signaling pathway
hsa04514 Cell adhesion molecules (CAMs)
hsa04650 Natural killer cell mediated cytotoxicity
hsa04668 TNF signaling pathway
hsa04670 Leukocyte transendothelial migration
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-1474244: Extracellular matrix organization
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-216083: Integrin cell surface interactions
R-HSA-913531: Interferon Signaling
R-HSA-877300: Interferon gamma signaling
R-HSA-6783783: Interleukin-10 signaling
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-449147: Signaling by Interleukins
Summary
SymbolICAM1
Nameintercellular adhesion molecule 1
Aliases CD54; human rhinovirus receptor; P3.58; ICAM-1; cell surface glycoprotein P3.58; intercellular adhesion mole ......
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ICAM1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ICAM1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27030019Renal Cell CarcinomaPromote immunity (T cell function)This study shows that overproduction of prostaglandin (PG) E2by metastatic murine renal carcinoma (Renca) cells inhibited direct priming of tumor-specific CTL responsesin vivoby preventing the IFNγ-dependent upregulation of ICAM-1 that is vital during the initial priming of na?ve CD8+T cells.
18268541NeuroblastomaPromote immunity (T and NK cell function)This manifests as increased expression of surface major histocompatibility class I complexes and ICAM-1 molecules and translates into increased sensitivity of NB cells to lysis by cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells.
28783722MelanomaPromote immunity (T cell function); essential for immunotherapyLoss of expression of these 19 genes within tumours could diminish or extinguish the presentation of tumour antigens (including HLA-A, HLA-F, B2M, TAP1 and TAP2); T cell co- stimulation (ICAM1, CLECL1, LILRA1 and LILRA3); or cytokine production and signalling (JAK2 and STAT1) in the tumour microenvironment that drive infiltration and activation of T cells, and thus serve as a principal mechanism in immune evasion.
23580577LymphomaPromote immunityMarked elevations in expression of activation receptors, natural cytotoxicity receptors (NKp30, NKp44), and adhesion molecules (CD11a, ICAM-1) were associated with high tumor-lytic capacity, in both in vitro and in vivo models.
19520829GliomaPromote immunity (T cell function)Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Taken together, Dicer is responsible for the generation of the mature miR-222 and -339, which suppress ICAM-1 expression on tumor cells, thereby down-regulating the susceptibility of tumor cells to CTL-mediated cytolysis.
24039573Kaposi SarcomaPromote immunity (infiltration)Further analysis also identified that KSHV miRNAs can modulate activity or expression of upstream regulatory factors, resulting in suppressed activation of a protein involved in leukocyte recruitment (ICAM1) following lysophosphatidic acid treatment, as well as up-regulation of a pro-angiogenic protein (HIF1α), and up-regulation of a protein involved in stimulating angiogenesis (HMOX1).
20100959Intermediate Atypical Prostate CarcinomaPromote immunityPROSTVAC-VF comprises two recombinant viral vectors, each encoding transgenes for PSA, and three immune costimulatory molecules (B7.1, ICAM-1, and LFA-3).
16081691Chronic Lymphocytic LeukemiaPromote immunity (T cell function)We have investigated the ability of in vitro manipulated CLL cells, via hyperexpression of a triad of costimulatory molecules (B7-1, intercellular adhesion molecule 1 [ICAM-1], and leukocyte-function-associated antigen 3 [LFA-3], designated TRICOM), to stimulate effective antitumor T-cell responses.
20513002Colon CarcinomaInhibit immunityManR expression and endocytosis increased in tumor-activated LSECs through a two-step mechanism: (1) Release of COX-2-dependent IL-1-stimulating factors by lymphocyte function-associated antigen-1-expressing C26 cells in response to intercellular adhesion molecule-1 (ICAM-1), which was expressed and secreted by tumor-activated LSECs; and (2) widespread up-regulation of ManR in LSECs through tumor-induced IL-1. ICAM-1-induced tumor COX-2 decreased antitumor activity during hepatic metastasis through IL-1-induced ManR.
17473183Metastatic MelanomaPromote immunity (infiltration)Results show that the majority of metastatic melanoma samples examined do not express the vascular adhesion receptors E-selectin (CD62E), P-selectin (CD62P), and intercellular adhesion molecule-1 (CD54) on vessels within the tumor boundaries. This results in a block to recruitment of activated tumor-specific CTL to melanoma metastases and is a likely factor limiting the effectiveness of current immunotherapy protocols.
21926464MelanomaPromote immunity (infiltration)Inflammatory cytokines such as IL-6 exert tumor-promoting activities by driving growth and survival of neoplastic cells. Mechanistically, IL-6 produced by nonhematopoietic stromal cells acted cooperatively with soluble IL-6 receptor-α and thermally induced gp130 to promote E/P-selectin- and ICAM-1-dependent extravasation of cytotoxic T cells in tumors.
21805477Hepatocellular CarcinomaPromote immunity (infiltration)Calreticulin (CRT), a chaperone protein mainly located in the endoplasmic reticulum, has been shown to exert anti-angiogenic activity and inhibit tumor growth. Here, we demonstrate that in addition to inhibiting angiogenesis, CRT also enhances the expression of both ICAM-1 and VCAM-1 on tumor endothelial cells. This expression results in enhanced leukocyte-endothelial cell interactions and increased lymphocyte infiltration into tumors.
Summary
SymbolICAM1
Nameintercellular adhesion molecule 1
Aliases CD54; human rhinovirus receptor; P3.58; ICAM-1; cell surface glycoprotein P3.58; intercellular adhesion mole ......
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ICAM1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.54 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolICAM1
Nameintercellular adhesion molecule 1
Aliases CD54; human rhinovirus receptor; P3.58; ICAM-1; cell surface glycoprotein P3.58; intercellular adhesion mole ......
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ICAM1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4170.261
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.6150.832
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2810.888
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4640.491
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.1870.596
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.460.883
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0490.923
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2030.919
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1250.955
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.280.55
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4960.644
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0670.718
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ICAM1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolICAM1
Nameintercellular adhesion molecule 1
Aliases CD54; human rhinovirus receptor; P3.58; ICAM-1; cell surface glycoprotein P3.58; intercellular adhesion mole ......
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ICAM1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolICAM1
Nameintercellular adhesion molecule 1
Aliases CD54; human rhinovirus receptor; P3.58; ICAM-1; cell surface glycoprotein P3.58; intercellular adhesion mole ......
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ICAM1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ICAM1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolICAM1
Nameintercellular adhesion molecule 1
Aliases CD54; human rhinovirus receptor; P3.58; ICAM-1; cell surface glycoprotein P3.58; intercellular adhesion mole ......
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ICAM1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolICAM1
Nameintercellular adhesion molecule 1
Aliases CD54; human rhinovirus receptor; P3.58; ICAM-1; cell surface glycoprotein P3.58; intercellular adhesion mole ......
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ICAM1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolICAM1
Nameintercellular adhesion molecule 1
Aliases CD54; human rhinovirus receptor; P3.58; ICAM-1; cell surface glycoprotein P3.58; intercellular adhesion mole ......
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ICAM1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolICAM1
Nameintercellular adhesion molecule 1
Aliases CD54; human rhinovirus receptor; P3.58; ICAM-1; cell surface glycoprotein P3.58; intercellular adhesion mole ......
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ICAM1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting ICAM1.
ID Name Drug Type Targets #Targets
DB00108NatalizumabBiotechC1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......12
DB08818Hyaluronic acidSmall MoleculeC1QBP, CD44, HABP2, HABP4, HAPLN1, HAPLN3, HAPLN4, HMMR, ICAM1, IM ......15
DB12598NafamostatSmall MoleculeF10, F12, F2, ICAM1, KLK1, PRSS16